COMPANY UPDATES
21
Jan
2020
Novoheart Contracts with Global Pharma to Develop Novel Microplate for High Throughput Drug Screening Using Engineered Human Heart Tissue Strips

Novoheart is pleased to announce the completion of a research and development contract sponsored by a top 10 global pharma. The contract deliverables will see Novoheart further expand its current testing capabilities of the MyHeartTM Platform by designing and developing a new versatile High-Throughput microplate which will allow the screening of hundreds of drugs using engineered human ventricular Cardiac Tissue Strips (hvCTS). Termed the hvCTS-96, the disposable microplate is a custom-designed plate with 96 "wells" used to simultaneously cultivate 96 individual miniature hvCTS, and will be compatible with robotic plate handling systems for automated high-throughput screening.

Novoheart’s MyHeartTM Platform, which includes its ‘human heart-in-a-jar’ technology, is providing engineered human cardiac tissue models for testing the efficacy and safety of drugs to predict human responses with more accuracy. The hvCTS-96 will increase the breadth and depth of the MyHeartTM Platform by offering a range of complementary but distinctive novel technologies to clients. The microplate market is estimated at CAD$980M (USD$750M).

For more detailed press release, please click here.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!